News Sentiment

LIMN sentiment intelligence

Liminatus Pharma, Inc. Class A Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 65 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.12 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+7.5% over one week, +3.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

$Liminatus Pharma (LIMN.US)$

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 7.5% Price confirming higher
Trend fit Trend inactive 3.2% over four weeks
Fair value -95.5% Below fair value
Market Dynamics buy signal Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 42
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
Market source 9
Stock Titan 9
Investing.com Nigeria 6
Moomoo 3
Benzinga 3
GlobeNewswire 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 17
Deals and strategy 11
Regulatory and legal 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 65
Moomoo Direct company coverage

Press Release: Liminatus Pharma Amends Definitive Merger Agreement With InnocsAI to Expand Oncology Cell Therapy Pipeline

Liminatus Pharma has amended its definitive merger agreement with InnocsAI, acquiring an exclusive global license for InnocsAI's AI-driven oncology cell therapy programs. This strategic move is expected to expand Liminatus's pipeline, particularly in areas like breast cancer and

Tone
Neutral 50/100
Event
Deals and strategy
Published
01 Jul 2026 14:41
Source
Moomoo
Investing.com Nigeria Direct company coverage

Form PRE 14A Liminatus Pharma Inc For: 30 June By Investing.com

This article announces the filing of Form PRE 14A by Liminatus Pharma Inc for June 30. It is a brief, factual update from Investing.com, providing basic financial market data alongside the news. The filing itself is not detailed, but the article contextualizes it within a broader

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 03:39
Source
Investing.com Nigeria
The Manila Times Direct company coverage

Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline

Liminatus Pharma, Inc. has amended its definitive merger agreement with InnocsAI LLC, an oncology biotechnology company, to strategically expand its oncology cell therapy pipeline. The re-structured transaction, now valued at approximately $320 million, is expected to close on Ju

Tone
Positive 76/100
Event
Deals and strategy
Published
01 Jul 2026 02:36
Source
The Manila Times
Investing.com Direct company coverage

Liminatus amends InnocsAI merger, closing set for July 2

Liminatus Pharma, Inc. has amended its merger agreement with InnocsAI LLC, with the closing now expected on July 2, 2026. The revised terms involve InnocsAI equity holders receiving Liminatus common stock and non-voting convertible preferred stock, valued at approximately $320 mi

Tone
Negative 19/100
Event
Deals and strategy
Published
30 Jun 2026 21:39
Source
Investing.com
Stock Titan Direct company coverage

Liminatus pushes $320M InnocsAI merger to July 2 close

Liminatus Pharma (Nasdaq: LIMN) has amended its definitive merger agreement with InnocsAI, restructuring the $320 million transaction to close on July 2, 2026, before obtaining stockholder approval. InnocsAI equity holders will receive Liminatus common and non-voting convertible

Tone
Positive 60/100
Event
Deals and strategy
Published
29 Jun 2026 18:10
Source
Stock Titan